Patients with high NfL levels had increased risk for worse disease outcomes.
Neurofilament light chain (NfL) in serum and cerebrospinal fluid is an indicator of axonal injury associated with multiple sclerosis (MS). To evaluate this molecule as a prognostic biomarker, investigators measured serum NfL in patients with relapsing-remitting MS enrolled in two phase III studies of fingolimod. In the FREEDOMS study, 269 participants received fingolimod or placebo for 24 months; in the TRANSFORMS study, 320 participants received fingolimod or interferon β-1a for 12 months.
Compared with 35 healthy controls (HC), patients with MS had higher baseline serum NfL (30.5 pg/mL [FREEDOMS], 27.0 pg/mL [TRANSFORMS], 16.9 pg/mL [HC]). High baseline NfL levels were positively associated with high volume of T2-weighted lesions as well a…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)